BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
2 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zou J, Li S, Wang Q, Mei J, Lu L, Lin W, Wen Y, Li Y, Wei W, Guo R. Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study. Cancer Med 2021;10:3274-87. [PMID: 33932132 DOI: 10.1002/cam4.3894] [Reference Citation Analysis]
4 Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia 2022;39:97-107. [PMID: 34979845 DOI: 10.1080/02656736.2021.2021303] [Reference Citation Analysis]
5 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
6 Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Nihonmatsu H, Hara K, Chuma M, Tsurugai Y, Maeda S. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study. BMC Cancer 2021;21:1169. [PMID: 34717577 DOI: 10.1186/s12885-021-08897-z] [Reference Citation Analysis]
7 Giannini EG, Bodini G, Furnari M, Marabotto E. Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. Liver Cancer 2019;8:524-6. [PMID: 31799210 DOI: 10.1159/000501485] [Reference Citation Analysis]
8 Guo Z, Zhong N, Xu X, Zhang Y, Luo X, Zhu H, Zhang X, Wu D, Qiu Y, Tu F. Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features. J Hepatocell Carcinoma 2021;8:773-82. [PMID: 34277508 DOI: 10.2147/JHC.S316117] [Reference Citation Analysis]
9 Kim GH, Kim JH, Shim JH, Ko HK, Chu HH, Shin JH, Yoon HK, Ko GY, Gwon DI. Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function: Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort. Life (Basel) 2021;11:840. [PMID: 34440584 DOI: 10.3390/life11080840] [Reference Citation Analysis]
10 Musa NI, Mohamed IE, Abohalima AS. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00035-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Boix L, Reig M. Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:426. [PMID: 33498698 DOI: 10.3390/cancers13030426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
13 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Chu HH, Kim JH, Shim JH, Gwon DI, Ko HK, Shin JH, Ko GY, Yoon HK, Kim N. Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2830. [PMID: 34204125 DOI: 10.3390/cancers13112830] [Reference Citation Analysis]
15 Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105-117. [PMID: 31372364 DOI: 10.2147/jhc.s168682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Li J, Guo C, Wu J. Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent. Drug Des Devel Ther 2020;14:2275-85. [PMID: 32606597 DOI: 10.2147/DDDT.S230749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
17 Tsilimigras DI, Moris D, Hyer JM, Bagante F, Sahara K, Moro A, Paredes AZ, Mehta R, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Sasaki K, Rodarte AI, Aucejo FN, Pawlik TM. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 2020;107:854-64. [PMID: 32057105 DOI: 10.1002/bjs.11464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
18 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu ZJ, Xie YF, Chang X, Zhang L, Wu HY, Liu JB, Zhang JX, Sun P. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization. Med Sci Monit 2021;27:e929884. [PMID: 33967266 DOI: 10.12659/MSM.929884] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]